Your browser doesn't support javascript.
loading
How should anti-hypertensive medications be adjusted before screening for primary aldosteronism?
Lu, Jin-Ying; Chang, Yi-Yao; Lee, Ting-Wei; Wu, Ming-Hsien; Chen, Zheng-Wei; Huang, Yen-Ta; Lai, Tai-Shuan; Er, Leay Kiaw; Lin, Yen-Hung; Wu, Vin-Cent; Cheng, Hao-Min; Kao, Hsien-Li; Jia-Yin Hou, Charles; Wu, Kwan-Dun; Chen, Szu-Tah; Liu, Feng-Hsuan.
  • Lu JY; Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: jinyinglu@ntuh.gov.tw.
  • Chang YY; Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. Electronic address: rollerpapa@gmail.com.
  • Lee TW; Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Division of Endocrinology and Metabolism, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Elec
  • Wu MH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan City, Taiwan; Division of Endocrinology and Metabolism, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (built and Operated by Chang Gung Medical Foundation), New T
  • Chen ZW; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan. Electronic address: librajohn7@hotmail.com.
  • Huang YT; Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address: uncleda.huang@gmail.com.
  • Lai TS; Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Primary Aldosteronism Center at National Taiwan University Hospital, Taipei, Taiwan. Electronic address: d99849016@ntu.edu.tw.
  • Er LK; The Division of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; School of Medicine, Tzu-Chi University, Hualien, Taiwan. Electronic address: leay29010@gmail.com.
  • Lin YH; Primary Aldosteronism Center at National Taiwan University Hospital, Taipei, Taiwan; Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: austinr34@gmail.com.
  • Wu VC; Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Primary Aldosteronism Center at National Taiwan University Hospital, Taipei, Taiwan. Electronic address: q91421028@ntu.edu.tw.
  • Cheng HM; Department of Medicine, National Yang Ming Chiao Tung University College of Medicine, Taipei, Taiwan; Institute of Public Health, National Yang Ming Chiao Tung University College of Medicine, Taipei, Taiwan; Center for Evidence-based Medicine, Taipei Veterans General Hospital, Taiwan. Electronic add
  • Kao HL; Division of Cardiology, Department of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: hsienli_kao@yahoo.com.
  • Jia-Yin Hou C; Cardiovascular Center, MacKay Memorial Hospital, Taipei, Taiwan. Electronic address: jiayinhou@gmail.com.
  • Wu KD; Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: kdwu@ntuh.gov.tw.
  • Chen ST; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan. Electronic address: stc1105@cgmh.org.tw.
  • Liu FH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address: fenghsuanliu@gmail.com.
J Formos Med Assoc ; 123 Suppl 2: S91-S97, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37291044
ABSTRACT
Anti-hypertensive medications may affect plasma renin activity and/or plasma aldosterone concentration, misleading the interpretation of the aldosterone-to-renin ratio when screening for primary aldosteronism. The Task Force of Taiwan PA recommends that, when necessary, using α-adrenergic receptor blocking agents, centrally acting α-adrenergic agonists, and/or non-dihydropyridine calcium channel blockers should be considered to control blood pressure before screening for PA. We recommend temporarily holding ß-adrenergic receptor blocking agents, mineralocorticoid receptor antagonists, dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and all diuretics before screening for PA. Further large-scale randomized controlled studies are required to confirm the recommendations.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hiperaldosteronismo / Hipertensión Tipo de estudio: Clinical_trials / Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hiperaldosteronismo / Hipertensión Tipo de estudio: Clinical_trials / Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article